Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Smart Nanoparticle Drug Delivery System Avoids Tumor-Protecting Obstacles

By LabMedica International staff writers
Posted on 13 Apr 2016
As a clearer image of the tumor microenvironment emerges, nanoparticle drug transport systems have evolved to overcome obstacles that prevent effective delivery of the chemotherapeutic agent.

A pertinent example is the triple-stage "cluster bomb" approach that has been developed by researchers at Emory University (Atlanta, GA, USA) and their colleagues at the University of Science and Technology of China (Hefei). 

The smart polymeric clustered nanoparticles (iClusters) developed by these investigators had an initial size of approximately 100 nanometers, which was favorable for long-term blood circulation and induced the particles to collect at tumor sites. More...
Once the iCluster particles accumulated at tumor sites, the intrinsic tumor extracellular acidity triggered the discharge of platinum prodrug-conjugated poly(amidoamine) dendrimers (diameter about five nanometers). Such a structural alteration promoted tumor penetration and cell internalization of the therapeutics. The internalized dendrimer prodrugs were further reduced intracellularly to release the drug cisplatin to kill the cancer cells.

The investigators reported in the March 28, 2016, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that they had validated the superior in vivo antitumor activities of the iCluster particles in several intractable mouse tumor models including poorly permeable pancreatic cancer, drug-resistant cancer, and metastatic cancer, which demonstrated their versatility and broad applicability.

"The negative side effects of cisplatin are a long-standing limitation for conventional chemotherapy," said contributing author Dr. Jinzhi Du, a postdoctoral researcher at Emory University. "In our study, the delivery system was able to improve tumor penetration to reach more cancer cells, as well as release the drugs specifically inside cancer cells through their size-transition property."

Related Links:

Emory University
University of Science and Technology of China



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
All-in-One Molecular System
AIO M160
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.